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Abstract 
 
Background:  
We explored the safety of intravenous thrombolysis (IVT) or intra-arterial treatment (IAT) in 
ischemic stroke patients on novel oral anticoagulants (NOAC, last intake <48hours) compared 
to patients (i) taking vitamin K-antagonists (VKA) or (ii) without prior anticoagulation (no-
oAC). 
 
Methods and Results:  
Multicenter cohort pilot study. Primary outcome measures were (i) occurrence of ICH in three 
categories - any intracranial hemorrhage (ICHany), symptomatic ICH according to the criteria 
of the ECASS-II (sICHECASS-II) and the NINDS thrombolysis trial (sICHNINDS); and (ii) death 
(at 3 months). Secondary outcomes included favorable 3-months outcome (modified Rankin 
Scale score 0-2). Cohorts were compared by using propensity score matching. Our NOAC 
cohort comprised of 78 patients treated with IVT/IAT and the comparison groups of 441 
VKA-patients and 8938 no-oAC patients. The median time from last NOAC intake to 
IVT/IAT was 13 hours (IQR 8-22h). In VKA-patients median pre-IVT/IAT INR was 1.3 (IQR 
1.1-1.6). ICHany was observed in 18.4% NOAC patients versus 26.8% VKA patients and 
17.4% no-oAC patients. sICHECASS-II and sICHNINDS occurred in 2.6%/3.9 % NOAC patients, 
compared to 6.5%/9.3% VKA patients and 5.0%/7.2% no-oAc patients, respectively. At 3 
months, 23.0% NOAC patients compared to 26.9% VKA patients and 13.9% no-oAC patients 
had died. Propensity score matching revealed no statistical significant differences. 
 
Conclusion: 
IVT/IAT in selected patients with ischemic stroke under NOAC treatment has a safety profile 
similar to both, IVT/IAT in patients on subtherapeutic VKA-treatment or in those without 
prior anticoagulation. However, further prospective studies are needed, including the impact 
of specific coagulation tests. 
 
Key words: intravenous thrombolysis, novel oral anticoagulants, vitamin K antagonists, 
ischemic stroke, intra-arterial treatment, endovascular treatment intracranial hemorrhage 
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Introduction 
Atrial fibrillation is one of the major risk factors for ischemic stroke1. Novel oral 
anticoagulants (NOAC) are at least as effective as Vitamin K-antagonists (VKA) in 
preventing ischemic stroke in patients with atrial fibrillation, with a better safety profile, 
especially for intracranial bleeding2-4. VKA act as indirect anticoagulants which lower the 
functional level of different vitamin-K dependent coagulation factors. In contrast, NOAC 
directly target selected players in the coagulation cascade as the direct thrombin inhibitor 
dabigatran or the factor-Xa inhibitors apixaban, rivaroxaban and edoxaban2,5. Therefore, onset 
of the anticoagulatory effect of NOACs is sudden (peak levels between 2 and 5 hours after 
intake). Anticoagulation lasts only for several hours to a few days while treatment with VKA 
results in a sustained, long lasting inhibition of the coagulation cascade6. 
1-2% of all individuals have atrial fibrillation, a proportion that will increase as populations 
age and diagnostic procedures improve. Despite the best medical treatment with VKA or 
NOAC 1.11-3.24% of patients with atrial fibrillation will have a new ischemic stroke 
annually2. Furthermore, also patients taking VKA or NOAC for indications other than atrial 
fibrillation can get an acute stroke. Many of these patients will be evaluated at emergency 
rooms for eligibility for acute recanalization therapies. For patients with ischemic stroke being 
treated with VKA, there are both guidelines7 and register-based observational data8, 9 
indicating that the use of intravenous thrombolysis (IVT) or intra-arterial-treatment (IAT) can 
be safe under certain conditions.  
However, it remains uncertain how patients developing acute ischemic stroke while taking 
NOAC should be treated. Current guidelines consider IVT contraindicated, and mention the 
cautious use of IAT7. Currently, millions of patients with atrial fibrillation worldwide are 
treated with NOAC, a number that will continue to increase. Withholding acute recanalization 
therapies from all patients with acute stroke and a last intake of NOAC within 48 hours would 
deny a substantial number of acute stroke patients an effective treatment.  
Nevertheless, theoretical approaches to guide the use of IVT or IAT in stroke patients taking 
NOAC have been published10-13. Furthermore, a few case reports on the use of IVT in patients 
taking dabigatran14-18, rivaroxaban19-22 or apixaban23 or IAT while taking dabigatran24 
reported favorable clinical outcomes. Conversely, one patient with acute ischemic stroke 
under dabigatran had a fatal intracranial hemorrhage (ICH) associated with IVT25. Thus, 
currently, there is a lack of systematic outcome and safety data in patients with acute ischemic 
stroke under NOAC treatment at the time of IVT or IAT. Standardized data in large cohorts 
including any comparison group are not available. As a pilot project, we therefore 
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investigated the safety of IVT and IAT for acute ischemic stroke in patients taking NOAC. 
Findings in NOAC-patients were compared with (i) those taking VKA and (ii) patients 
without anticoagulation (no-oAC) prior to IVT/IAT in a large multicenter observational 
cohort study. 
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Material and Methods 
Study design and study population 
As a joint initiative of 25 European and Japanese stroke centers, we performed an 
observational collaborative cohort study to investigate: (i) the incidence of intracranial 
hemorrhages (ICH); and (ii) functional outcome of patients with acute ischemic stroke 
occurring under NOAC who were treated with IVT or IAT or both (i.e., bridging). IAT 
included intra-arterial thrombolysis, mechanical revascularization, or both. We introduced 
two comparisons groups: First, stroke patients with IVT and/or IAT under VKA and, second, 
patients without anticoagulation at the time of IVT/IAT. 
All participating centers applied IVT and IAT according to well-established criteria and 
guidelines7, 26 with the exception that in selected patients NOAC treatment was not considered 
an absolute exclusion criterion.  
 
Each center reported on all NOAC patients treated with IVT/IAT during the period for which 
they had prospectively recorded data on consecutive patients treated with IVT/IAT in local 
registries or lists since approval of the first NOAC for stroke prevention in atrial fibrillation in 
their country up to December 31st 2014. Selected centers also provided information on all 
stroke patients treated with IVT/IAT (i) under VKA and (ii) those without prior 
anticoagulation (no-oAC) based on local registries. For each contributing center, the number 
of patients, recruitment periods and type of data source (i.e. register versus patient lists) are 
summarized in online supplemental Table 1. 
 
Data collection 
Data for all patients were collected using a standardized form with predefined variables, 
following an approach utilized in prior research27-29. Local study investigators retrospectively 
completed the forms systematically using data from (i) prospectively ascertained in-hospital 
thrombolysis or stroke-registries or (ii) from patients’ records and charts in case patients were 
selected and identified by local patients lists about consecutive IVT/IAT. Completed forms 
from all centers were sent to the coordinating center in Basel, where analyses of pooled data 
were performed. 
 
Baseline data 
The following variables were collected from the centers’ databases, registries or patients’ 
records as previously defined27-29: age, sex, stroke severity as assessed by the National 
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Institutes of Health Stroke Scale (NIHSS) score prior to IVT/IAT and after 24 hours, 
international normalized range (INR), presence or absence of main intracranial arteries 
occlusion (assessed by CTA or MRA), blood pressure, time-to-treatment and etiology 
according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria. A 
descriptive summary is given in Table 1. In addition, the following vascular risk factors were 
collected according to predefined criteria27: hypertension, diabetes, hypercholesterolemia, 
coronary artery disease, history of prior ischemic stroke. Prior use of antiplatelet drugs, 
antihypertensive drugs, and statins was assessed30. Laboratory measures prior to IVT/IAT 
included blood glucose levels, creatinine27, platelet count, international normalized ratio, 
activated Partial Thromboplastin Time (aPTT), and calibrated anti factor-Xa assays for 
rivaroxaban, if available and applicable. Current use of VKA or NOAC was recorded. In 
patients taking NOAC: agent and daily dosage, indication, last intake (in hours prior to 
IVT/IAT), and categorized reason for using IVT/IAT treatment were recorded. Functional 
outcome was assessed by outpatient visits or telephone interviews using the modified Rankin 
Scale (mRS) at 3 months. 
 
Outcome measures 
Primary outcome measures were defined as the occurrence of ICH in three categories, or 
death within 3 months (i.e., mRS of 6, denoted as mRS6). ICH included: (i) any ICH on 
follow-up imaging including hemorrhagic transformation (ICHany); (ii) symptomatic ICH 
according to the criteria of the ECASS-II trial31 (sICHECASS-II); and (iii) sICH based on the 
criteria of the NINDS thrombolysis trial32 (sICHNINDS). 
Secondary outcome measures were: (i) NIHSS after 24 hours; (ii) major neurological 
improvement within 24 hours, defined as an improvement in NIHSS score of 8 points at 24 
hours compared to initial NIHSS (or an NIHSS score of 0 at 24 hours) as defined in prior 
research33; and (iii) favorable 3-month outcome (i.e., mRS of 0, 1, or 2, denoted as mRS0-2). 
 
Subgroup analyses 
First, patients treated with IVT only (i.e., excluding those with IAT only) were analysed by 
comparing all groups. Second, in NOAC patients, all patients with IVT/IAT decisions based 
on the findings of the calibrated anti factor-Xa assays were descriptively analysed. Third, 
post-hoc, we compared NOAC patients with VKA patients stratified to the INR in 2 strata:  
VKA with INR >1.7 and those with INR ≤1.7. 
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Statistical analyses 
Propensity score matching was used for analyses. Due to the heterogeneous sample sizes 
between groups, we used triple group (TriMatch34) propensity score matching (PSM35) to 
balance characteristics of patients according to baseline covariates. Variables likely to affect 
outcome or complications were chosen based on previous studies27-30. The variables included 
as predictors in PSM were age, sex, time-to-treatment, admission NIHSS, systolic and 
diastolic blood pressure, blood glucose level, creatinine as well as prior medication with 
statins, antihypertensive agents or antiplatelets, and the presence of diabetes, hypertension, 
hypercholesterolemia, coronary artery disease, atrial fibrillation, and history of prior ischemic 
stroke. 
 
We employed a bootstrapping procedure36 that combined propensity score matching with 
multiple imputation37. Patients in the NOAC groups, VKA and no-oAC, and groups were then 
matched based on their propensity scores38. Subsequent statistical analyses were carried out 
on the matched samples. The procedure was repeated 50.000 times to gain a reliable bootstrap 
estimation of the empirical distribution of test statistics and p-values. 
 
Overall differences in NIHSS at 24 hours were analysed with univariate analysis of variance 
(ANOVA) with treatment group as the between subjects factor. Pairwise comparisons 
between treatment groups were computed as a-priori contrasts. Overall differences in the 
proportion of patients with ICHany, major neurological improvement, mRS0-2, and mRS6 were 
tested with χ² tests. Pairwise differences between treatment groups for ICHany, major 
neurological improvement, mRS0-2, and mRS6 were assessed with 2-sample binomial tests. 
Pairwise differences for sICHNINDS and sICHECASS-II were tested using Fisher’s exact test. 
Overall differences for sICHECASS-II and sICHNINDS could not be evaluated due to very low 
incident rates in the NOAC group. Only pairwise Fisher’s exact tests were computed. Odds 
ratios (OR) and their 95% confidence intervals are provided for all instances of statistical 
significance. 
 
In a post-hoc analysis, three subgroups of patients were defined: patients on VKA with INR 
>1.7 (VKA INR>1.7), patients on VKA with INR ≤1.7 (VKA INR≤ 1.7) and patients on NOAC. 
We conducted the same set of statistical tests as described before. Due to tolerable differences 
in sample sizes between the three groups, no propensity score matching was required. 
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Statistical analyses were performed using R for Windows, version 3.1.2. All tests were 2-
tailed, and statistical significance was determined at α level of 0.05. For pairwise tests 
between groups, α was corrected for multiple comparisons using the Šidák correction39. 
 
Ethics: The study was approved by the ethics committee in Basel Switzerland. The 
requirement for additional local ethical approval differed among participating centers and was 
acquired as necessary. 
 
Results 
Study population 
Our NOAC cohort comprised of 78 patients (apixaban n=2, dabigatran n=29 and rivaroxaban 
n=47). IVT was used in 51 NOAC patients, including 6 who received IVT followed by IAT. 
IAT only was used in 27 NOAC patients, in 25/27 patients with purely mechanical 
thrombectomy. The comparison groups comprised of (i) 441 VKA patients and (ii) 8938 no-
oAC patients (online supplemental Table 1). 
 
Baseline characteristics 
There were significant differences in baseline characteristics between all cohorts. Baseline 
characteristics and recanalization therapies applied are displayed in Table 1. 
 
Last intake, coagulation parameters and indication for NOAC treatment 
For NOAC patients, the median time between last intake and IVT/IAT was 13 hours (IQR 8-
22h); it was <12 hours in 38 patients, 13-24 hours in 30 patients, 25-48 hours in 7 patients; 
and unknown (but still within <48 hours) in 3 patients. Atrial fibrillation was the indication 
for the NOAC use in 69 of 78 (88%) patients. Other indications included prevention (n=2) 
and treatment (n=3) of deep vein thrombosis and other/ not recorded (n=4).  
In patients receiving rivaroxaban (n=47), the median INR was 1.3 (IQR 1.1-1.51) and the 
mean aPTT was 32 seconds (IQR 27-35 seconds); in patients receiving dabigatran (n=29), 
median INR was 1.3 (IQR 1.1-1.5) and mean aPTT 32 seconds (IQR 27-35 seconds). The 2 
patients under apixaban had an INR of 1.18 and 1.16 and an aPTT of 32 and 33 seconds, 
respectively.  
 
In the VKA-group, the median INR was 1.3 (IQR 1.1–1.58). In 308 VKA patients (69.8%), 
the INR was ≤ 1.7. In 80 VKA patients (18.1%) no INR was recorded. Among the 53 VKA-
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patients (12%) with INR >1.7 (INR median 2.0; IQR 1.9-2.35), 37 were treated with IVT, 
while 16 had IAT (INR median 2.15, IQR 2.0-2.87).  
 
The decision to use IVT/IAT in NOAC patients was based on the reported time since last 
intake >24 hours (n=10), low concentrations levels in drug-specific coagulation assays 
(n=23), on normal values in routine coagulation assays (n=10), or on other/or unknown 
reasons (n=35). The latter included patients, in which the use of NOAC was neither known 
nor suspected prior to IVT/AT treatment but was discovered thereafter. 
 
Outcome measures 
 
Primary outcome measures: ICHany was observed in 14 of 76 (18.4%) NOAC patients 
compared to 105 of 394 (26.6%) on VKA patients, and 1332 of 7677 (17.4%)  patients in the 
no-oAC group. (p = .304). sICHECASS-II occurred in 2 of 76 (2.6%) NOAC-patients compared 
to 27 of 415 (6.5%) VKA-patients and 417 of 8281 (5.0%) no-oAC patients ((p = .484). 
sICHNINDS was reported for 3 of 76 (3.9%) NOAC-patients, c, 40 of 432 (9.3%) VKA-patients 
and 616 of 8539 (7.2%) no-oAC patients (p = .560). At 3 months, 17 of 74 (23.0%) NOAC-
patients had died compared to 113 of 420 (26.9%) VKA-patients and 1172 of 8414 (13.9%) 
no-oAC patients(p = .438) (Table 2). 
 
Secondary outcome measures:  A favorable 3-month outcome had  30 of 74 (40.5%) NOAC-
patients compared to 166 of 420 (39.5%) VKA-patients and 4736 of 8414 (56.3%) no-oAC 
patients. Here, we find the only significant overall difference of frequencies in our data (p = 
.037). The pattern of frequencies suggests a more favorable 3-month outcome for no-oAC 
patients than for the VKA and the NOAC-patients. Pairwise comparisons, however, remain 
insignificant in all cases (all p >.05). Major neurological improvement occurred similarly 
often in all three groups (Table 2) 
 
Subgroup analyses 
IVT only:  
IVT only was used in  51 NOAC   and 390 VKA patients . ICHany occurred in 8 (15.7%) 
patients on NOAC and 54 (28.7%) patients on VKA.. sICHECASS-II and sICHNINDS occurred in 
2 (4.0%) patients on NOAC each, compared to 7 (3.6%) and 11 (5.7%) patients on VKA.  
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IVT/IAT and calibrated anti factor-Xa assays 
In 21 taking rivaroxaban), decision to administer IVT was based on calibrated anti factor Xa-
assays with a mean level of 21ng/ml (IQR 8-23ng/ml). In all patients on rivaxoraban receiving 
IVT measured anti factor Xa-levels were below 100ng/ml. Each of those 3 patients with a 
measured anti factor Xa-levels of > 100ng/ml (range 146-246ng/ml) had IAT only. None had 
sICH.  
 
NOAC and VKA INR>1.7 or VKA INR≤ 1.7 
Primary and secondary outcome measures for the subgroup analysis comparing patients on 
NOAC and VKA INR>1.7 or VKA INR≤ 1.7 are summarized in table 3. Pairwise Fisher’s Exact 
Tests reveals a significant pairwise difference for sICHECASS-II only between VKA INR>1.7 
(n=16, 11.9%) and VKA INR≤ 1.7(n=24, 8.1%, OR = 2.751; [1.963, 3.539]) but not for any 
other outcome measure or between other groups.  
 
Discussion 
This observational multicenter pilot study yielded the following key findings: first, in selected 
patients with acute ischemic stroke who are on current NOAC treatment (last intake <i48 
hours), IVT/IAT was feasible and not associated with an excessive risk of ICH compared to 
patients on VKA or without oral anticoagulation . Second, compared to VKA patients NOAC 
patients had – numerically - fewer intracranial hemorrhages, lower death rates, and a better 
functional outcome. However, none of these differences reached statistical significance. 
 
Overall, our study highlights that – at least in experienced stroke centers - IVT/IAT 
application in carefully selected acute ischemic stroke patients under NOAC treatment did not 
raise any suggestion of safety concerns.  
The percentage of sICHECASS-II (2.6%) or sICHNINDS (3.9%) in our NOAC cohort was 
comparable to sICH rates in a recent multicenter analysis (i.e. 4.7%)40 and in the ECASS-3 
study (5.3%)41. However, this finding might not be necessarily reassuring, as the upper limit 
of the 95%CI (i.e. 6.13% for sICHECASS-II  and 8.2%for ICHNINDS, respectively) indicates that 
the sICH risk might still be higher than that of reported data. Nevertheless, based on the 
observation that the ICH risk in all categories was numerically lower in NOAC than in VKA 
patients, this scenario seems unlikely, especially taking into account that IVT/IAT in VKA 
patients has generally been reported to be safe8, 9. Reasons for this relative safety of IVT/IAT 
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under NOAC may include the lower baseline risk of ICH of such drugs, including in stroke 
patients3. 
 
 
In approximately 25% of the NOAC treated patients, the decision to use IVT/IAT was based 
on rivaroxaban concentration levels in the calibrated anti factor Xa-assay. The same approach 
has also been utilized in two recent case reports19, 21. All these patients treated with IVT (i.e., 
from the mentioned case reports and our cohort) had levels of the calibrated anti factor Xa-
assay <100ng/ml. None of these altogether 24 patients had sICH and only 1 had an 
asymptomatic ICH. Thus this threshold, recommended previously based on purely theoretical 
and pharmacological considerations and data11, may indeed serve as a clinically useful tool to 
select patients. However, given the small sample size our results should be interpreted with 
caution. Thus, further research about the clinical meaning of NOAC concentration thresholds 
is still needed.  
 
Our analysis had the following strengths: (i) We report on a multicenter cohort rather than on 
a single or several cases of acute ischemic stroke while under treatment with NOAC; (ii) data 
ascertainment was undertaken systematically and included two comparison groups (i.e., VKA 
patients and patients without prior anticoagulation with IVT/IAT); and (iii) safety issues as 
well as functional outcome at 3 months were addressed.  
Nevertheless, several potential limitations should be noted: First, this is a retrospective study. 
Second, there was heterogeneity between centers with regard to the criteria applied for the 
decision to use or avoid IVT/IAT in individual patients, and whether IVT or IAT was 
preferred. Third, NOAC patients differed from the VKA- and the no-oAC-patients in several 
baseline characteristics. Despite application of propensity score matching as an effort to 
minimize confounding effects, we cannot rule out the possibility that unmeasured 
characteristics might have differed between these patients and confounded our results. Fourth, 
we do not have a comparison group of patients on NOAC and acute ischemic stroke not 
treated with IVT/ IAT, so the bleeding risk in acute ischemic stroke patients under NOAC 
treated with IVT/IAT versus those without IVT/IAT could not be studied. Fifth, despite being 
the largest cohort available so far, the total numbers of patients taking NOAC or VKA are still 
relatively small. Thus, subgroup analyses, including patients with results of drug specific 
coagulation assays were limited. Therefore, we stress the pilot character of our study and urge 
to a cautious interpretation of our findings. 
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While safety of IVT in patients on VKA and an INR less or equal to 1.7 is has been 
established based on large cohorts8, 9, knowledge about NOAC is extremely limited in 
comparison. The use of IVT in patients under NOAC has been reported only in single cases so 
far showing feasibility14-18, 20, 21, 24. Data from animal models showed no excessive risk of ICH 
after IVT in rodents with a prior treatment with rivaroxaban42, 43, dabigatran44, 45, and 
apixaban43 compared with VKA. Currently, the use of IVT for acute ischemic stroke in 
patients with a recent (<48 hours) intake of a NOAC is regarded off-label7. Indeed, a recent 
survey among US vascular neurologists showed a remarkable lack of consensus regarding the 
management of patients with acute ischemic stroke that were taking dabigatran.46 The 
guidelines of the American Heart Association/American Stroke Association state that IVT 
might be considered ”[if] sensitive laboratory tests such as aPTT, INR, platelet count, and 
ECT, TT, or appropriate direct factor Xa activity assays are normal, or the patient has not 
received a dose of these agents for >2 days (assuming normal renal metabolizing function)7. 
Nevertheless, NOAC have only limited influence on standard coagulation assays47. Practical 
approaches for the use of IVT and IAT in stroke patients on NOAC have been proposed10, 11. 
A recently developed and prospectively assessed approach for patients on dabigatran using 
aPTT and thrombin time in a US study reported 2 patients receiving IVT within 8 month of 
recruitment with no sign of ICH in these patients{Kate, 2014 #101}. No larger prospective 
study has yet evaluated the proposed thresholds. 
Twenty-seven of our NOAC patients were treated with IAT only; 25 of those with pure 
mechanical thrombectomy. SICH was absent in all patients and also in the only case report of 
mechanical thrombectomy in NOAC patient with acute stroke we are aware of24. Although 
these numbers were small, the absence of sICH might suggest, that in patients with abnormal 
hemostasis and NOAC-treatment, mechanical recanalization strategies might be more 
appropriate. However, it remains to be shown, whether sICH rates are indeed lower when 
NOAC-patients with acute stroke are treated with pure mechanical IAT than with IVT. For 
patients with abnormal hemostatasis48, 49 and treatment with IAT, sICH rates were 7.1%48 and 
11.4%49 which were  numerically higher than those observed in our NOAC cohort treated 
with IVT.   
 
In conclusion, our data suggest that IVT/IAT treatment in patients who have an acute 
ischemic stroke despite NOAC is feasible and probably not associated with an excessive risk 
for ICH. However, this assumption requires that patients (i) are treated in experienced stroke 
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centers and (ii) are carefully selected based on time from last intake of the oral anticoagulant 
and/or the findings of specific coagulation tests. Nevertheless, our observations must be 
considered with caution prior to generalizing them to standard practice. More research is 
needed, which should include a systematic assessment of the clinical meaning of coagulation 
tests and drug doses with regard to safety and effectiveness measures. With these 
considerations in mind, we set up a prospective multi-center registry to systematically 
investigate the management of patients with acute ischemic stroke while taking novel oral 
anticoagulants (NOACISP ACUTE, Cinicaltrials.gov: NCT02353585). 
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Table 1 Baseline characteristics of patients who had recanalization therapies while under treatment with a NOAC, a VKA or no-oAC. 
Novel oral anticoagulants Vitamin K antagonists no-oAC Statistics 
(n = 78) (n = 441) (n = 8938)  
Age in years, median (IQR) 76 (68-81) 77 (68-83) 71 (60-79) p < .001a 
Female gender, n (%) 36 (49.3%) 201 (45.6%) 3915 (43.9%) p = .495b 
Time-to-treatment time in minutes, median (IQR) 174.5 (115.5-240) 140 (90-185) 126 (80-175) p < .001a 
Baseline NIHSS score, median (IQR) 14.5 (7-19) 14 (8-19) 10 (6-16) p < .001a 
INR, median (IQR) 1.14 (1.06-1.3) 1.3 (1.1-1.6) 1 (1-1.1) p < .001a 
Occlusion of intracranial artery, n (%) 50 (75.8%) 174 (68.5%) 2070 (46.7%) p < .001b 
Systolic blood pressure in mm Hg, mean (IQR) 148 (127.5-164.5) 151.5 (132-170) 154 (139-170) p = .148a 
Diastolic blood pressure in mm Hg, mean (IQR) 80 (67-93.5) 83 (73-94) 83 (74-94) p = .175a 
Type of acute recanalization therapy     
IV thrombolysis only, n (%) 45 (57.7%) 354 (84.9%) 7788 (93.2%) p = n.a.c 
IV thrombolysis and IA treatment, n (%) 6 (7.69%) 36 (8.63%) 521 (6.24%)  
IA treatment only, n (%) 27 (34.62%) 27 (6.47%) 43 (0.51%)  
Concomitant treatment    
Prior use of statins, n (%) 27 (39.1%) 160 (38%) 1954 (25.5%) p < .001b 
Prior use of antihypertensive drugs, n (%) 61 (87.1%) 346 (82.2%) 4424 (54.4%) p < .001b 
Prior treatment with antiplatelets, n (%)) 14 (18.2%) 64 (14.8%) 3008 (35.8%) p < .001b 
Risk factors    
Atrial fibrillation, n (%) 68 (87.2%) 345 (78.8%) 2152 (24.3%) p < .001b 
Diabetes mellitus, n (%) 17 (24.3%) 98 (22.2%) 1500 (16.8%) p = .066b 
Hypertension, n (%) 61 (87.1%) 349 (79.1%) 5627 (63.2%) p < .001b 
Hypercholesterolemia, n (%) 32 (49.2%) 184 (42.5%) 3559 (41.4%) p = .450b 
Coronary artery disease, n (%) 24 (34.3%) 107 (25.4%) 1371 (16.9%) p < .001b 
Prior history of stroke, n (%) 18 (25.4%) 110 (25.4%) 1211 (14%) p < .001b 
Stroke Etiology (TOAST criteria)    
Cardioembolic, n (%) 64 (85.3%) 224 (61.4%) 2623 (33.1%) p = n.a.c 
Large artery atherosclerosis, n (%) 2 (2.7%) 97 (26.6%) 2003 (25.3%)  
Small artery occlusion, n (%) 0 (0%) 3 (0.82%) 574 (7.25%)  
Other, n (%) 1 (1.33%) 11 (3.01%) 338 (4.27%)  
More than 1 or undetermined, n (%) 8 (10.67%) 29 (7.95%) 2233 (28.21%)  
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Note: a Kruskal-Wallis test with df = 2 
 b χ²-test with df = 2 
 c No test computed due to low sample sizes in one or more subgroups 
 
 
Table 2: Primary and secondary outcome measures:  
 Novel oral anticoagulants Vitamin K antagonists no-oAC 
 (n = 78) (n = 441) (n = 8938) 
Primary outcome    
ICHany 14 of 76 (18.4%) 105 of 394 (26.6%) 1332 of 7677 (17.4%) 
sICHECASS-II 2 of 76 (2.6%) 27 of 415 (6.5%) 417 of 8281 (5.0%) 
sICHNINDS 3 of 76 (3.9%) 40 of 432 (9.3%) 616 of 8539 (7.2%) 
Death at 3 months (mRS6) 17 of 74 (23.0%) 113 of 420 (26.9%) 1172 of 8414 (13.9%) 
Secondary outcome    
NIHSS at 24 hours, median (IQR) 9 (2-14) 8 (3-16) 5 (2-13) 
Major neurologic improvement 24 of 77 (31.2%) 128 of 405 (31.6%) 1958 of 6834 (28.7%) 
Favorable clinical outcome at 3 months (mRS0-2) 30 of 74 (40.5%) 166 of 420 (39.5%) 4736 of 8414 (56.3%) 
 
Definitions: 
ICHany – any hemorrhage seen on follow-up imaging 
sICHECASS-II – any hemorrhage with neurologic deterioration, as indicated by an NIHSS score that was higher by >/= 4 points than the value at 
baseline or the lowest value in the first 7 days, or any hemorrhage leading to death.  
sICHNINDS – any hemorrhage on follow-up imaging and any decline in neurological status 
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Major neurologic improvement – improvement in NIHSS score of 8 points at 24 hours compared to initial NIHSS (or NIHSS score of 0 at 24 hours) 
 
Table 3: Outcome measures stratified to VKA with INR subgroups versus NOAC patients:  
 Vitamin K antagonists   Novel oral anticoagulants 
 INR >1.7 INR ≤1.7  (n = 78) 
 (n = 135) (n = 306)   
Primary outcome     
ICHany 36 of 123 (29.27%) 69 of 271 (25.46%)  14 of 76 (18.42%) 
sICHECASS-II 13 of 116 (11.21%) 14 of 299 (4.68%)  2 of 76 (2.63%) 
sICHNINDS 16 of 135 (11.85%) 24 of 297 (8.08%)  3 of 76 (3.95%) 
Death at 3 months (mRS6) 38 of 129 (29.46%) 75 of 291 (25.77%)  17 of 74 (22.97%) 
Secondary outcome     
NIHSS at 24 hours, median (IQR) 9 (3-17) 8 (3-16)  9 (2-14) 
Major neurologic improvement 42 of 123 (34.15%) 86 of 282 (30.50%)  24 of 77 (31.17%) 
Favourable clinical outcome at 3 months (mRS0-2) 57 of 129 (44.19%) 109 of 291 (37.46%)  30 of 74 (40.54%) 
 
Note: Definitions as in Table 2. 
 
 
17 
 
References: 
 
1. Lip GY, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: A 
systematic review of the epidemiology of atrial fibrillation in regions outside north 
america and europe. Chest. 2012;142:1489-1498 
2. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention 
in non-valvular atrial fibrillation. Lancet Neurol. 2012;11:1066-1081 
3. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-k-
antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or 
transient ischemic attack: A systematic review and meta-analysis of randomized 
controlled trials. Stroke. 2012;43:3298-3304 
4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, 
Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. 
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in 
patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet. 
2014;383:955-962 
5. Weitz JI. New oral anticoagulants: A view from the laboratory. American journal of 
hematology. 2012;87 Suppl 1:S133-136 
6. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor xa and thrombin inhibitors 
in the management of thromboembolism. Annual review of medicine. 2011;62:41-57 
7. Jauch EC, Saver JL, Adams HP, Jr., Bruno A, Connors JJ, Demaerschalk BM, Khatri 
P, McMullan PW, Jr., Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, 
Wintermark M, Yonas H. Guidelines for the early management of patients with acute 
ischemic stroke: A guideline for healthcare professionals from the american heart 
association/american stroke association. Stroke. 2013;44:870-947 
8. Mazya MV, Lees KR, Markus R, Roine RO, Seet RC, Wahlgren N, Ahmed N. Safety 
of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. 
Annals of neurology. 2013:266-274 
9. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, 
Fonarow GC, Peterson ED. Risks of intracranial hemorrhage among patients with 
acute ischemic stroke receiving warfarin and treated with intravenous tissue 
plasminogen activator. JAMA : the journal of the American Medical Association. 
2012;307:2600-2608 
10. Brouns R, Van Hooff RJ, De Smedt A, Moens M, De Raedt S, Uyttenboogaart M, 
Luijckx GJ, Jochmans K, De Keyser J. Acute stroke management in patients taking 
dabigatran. CNS neuroscience & therapeutics. 2012;18:616-622 
11. Steiner T, Bohm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, 
Laufs U, Nickenig G, Riess H, Rother J, Schellinger PD, Spannagl M, Veltkamp R. 
Recommendations for the emergency management of complications associated with 
the new direct oral anticoagulants (doacs), apixaban, dabigatran and rivaroxaban. 
Clinical research in cardiology : official journal of the German Cardiac Society. 
2013;102:399-412 
12. Diener HC, Foerch C, Riess H, Rother J, Schroth G, Weber R. Treatment of acute 
ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-
thrombotic treatment. Lancet Neurol. 2013;12:677-688 
13. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients 
taking novel oral anticoagulants. Int J Stroke. 2014;9:627-632 
18 
 
14. Lee VH, Conners JJ, Prabhakaran S. Intravenous thrombolysis in a stroke patient 
taking dabigatran. Journal of stroke and cerebrovascular diseases : the official journal 
of National Stroke Association. 2012;21:916 e911-912 
15. Sangha N, El Khoury R, Misra V, Lopez G. Acute ischemic stroke treated with 
intravenous tissue plasminogen activator in a patient taking dabigatran with 
radiographic evidence of recanalization. Journal of stroke and cerebrovascular 
diseases : the official journal of National Stroke Association. 2012;21:917 e915-918 
16. Testai FD. Intravenous thrombolysis in a stroke patient taking dabigatran. Journal of 
stroke and cerebrovascular diseases : the official journal of National Stroke 
Association. 2013;22:894 
17. De Smedt A, De Raedt S, Nieboer K, De Keyser J, Brouns R. Intravenous 
thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated 
with dabigatran. Cerebrovascular diseases (Basel, Switzerland). 2010;30:533-534 
18. Pfeilschifter W, Abruscato M, Hovelmann S, Baas H. Thrombolysis in a stroke patient 
on dabigatran anticoagulation: Case report and synopsis of published cases. Case 
reports in neurology. 2013;5:56-61 
19. Fluri F, Heinen F, Kleinschnitz C. Intravenous thrombolysis in a stroke patient 
receiving rivaroxaban. Cerebrovascular diseases extra. 2013;3:153-155 
20. Kawiorski MM, Alonso-Canovas A, de Felipe Mimbrera A, Sainz de la Maza S, 
Alvarez-Velasco R, Zarza B, Masjuan J. Successful intravenous thrombolysis in acute 
ischaemic stroke in a patient on rivaroxaban treatment. Thromb Haemost. 2013;111 
21. Seiffge DJ, Traenka C, Gensicke H, Tsakiris DA, Bonati LH, Peters N, Lyrer P, 
Engelter ST. Intravenous thrombolysis in stroke patients receiving rivaroxaban. 
European Journal of Neurology. 2013:e3–e4 
22. van Hooff RJ, Nieboer K, De Smedt A, Yperzeele L, Jochmans K, De Keyser J, 
Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator 
for acute ischemic stroke in a patient treated with rivaroxaban. Clinical neurology and 
neurosurgery. 2014;122:133-134 
23. De Smedt A, M C, Nieboer K, Moens M, Van Hooff RJ, Yperzeele L, Jochmans K, 
De Keyser J, Brouns R. Intravenous thrombolysis with recombinant tissue 
plasminogen activator in a stroke patient treated with apixaban. Int J Stroke. 2014;in 
press 
24. Muller P, Topakian R, Sonnberger M, Nussbaumer K, Windpessl M, Eder V, Nesser 
HJ, Trenkler J, Haring HP. Endovascular thrombectomy for acute ischemic stroke 
patients anticoagulated with dabigatran. Clinical neurology and neurosurgery. 
2013;115:2257-2259 
25. Casado Naranjo I, Portilla-Cuenca JC, Jimenez Caballero PE, Calle Escobar ML, 
Romero Sevilla RM. Fatal intracerebral hemorrhage associated with administration of 
recombinant tissue plasminogen activator in a stroke patient on treatment with 
dabigatran. Cerebrovascular diseases (Basel, Switzerland). 2011;32:614-615 
26. Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y. Comparison 
of the european and japanese guidelines for the management of ischemic stroke. 
Cerebrovascular diseases (Basel, Switzerland). 2013;35:402-418 
27. Gensicke H, Zinkstok SM, Roos YB, Seiffge DJ, Ringleb P, Artto V, Putaala J, 
Haapaniemi E, Leys D, Bordet R, Michel P, Odier C, Berrouschot J, Arnold M, 
Heldner MR, Zini A, Bigliardi G, Padjen V, Peters N, Pezzini A, Schindler C, 
Sarikaya H, Bonati LH, Tatlisumak T, Lyrer PA, Nederkoorn PJ, Engelter ST. Iv 
thrombolysis and renal function. Neurology. 2013;81:1780-1788 
28. Scheitz JF, Seiffge DJ, Tutuncu S, Gensicke H, Audebert HJ, Bonati LH, Fiebach JB, 
Tranka C, Lyrer PA, Endres M, Engelter ST, Nolte CH. Dose-related effects of statins 
19 
 
on symptomatic intracerebral hemorrhage and outcome after thrombolysis for 
ischemic stroke. Stroke. 2014;45:509-514 
29. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, Putaala J, 
Haapaniemi E, Tatlisumak T, Chen Y, Leys D, Sarikaya H, Michel P, Odier C, 
Berrouschot J, Arnold M, Heldner MR, Zini A, Fioravanti V, Padjen V, Beslac-
Bumbasirevic L, Pezzini A, Roos YB, Nederkoorn PJ. Safety of thrombolysis in 
stroke mimics: Results from a multicenter cohort study. Stroke. 2013;44:1080-1084 
30. Engelter ST, Soinne L, Ringleb P, Sarikaya H, Bordet R, Berrouschot J, Odier C, 
Arnold M, Ford GA, Pezzini A, Zini A, Rantanen K, Rocco A, Bonati LH, Kellert L, 
Strbian D, Stoll A, Meier N, Michel P, Baumgartner RW, Leys D, Tatlisumak T, 
Lyrer PA. Iv thrombolysis and statins. Neurology. 2011;77:888-895 
31. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, 
Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P. 
Randomised double-blind placebo-controlled trial of thrombolytic therapy with 
intravenous alteplase in acute ischaemic stroke (ecass ii). Second european-
australasian acute stroke study investigators. Lancet. 1998;352:1245-1251 
32. Tissue plasminogen activator for acute ischemic stroke. The national institute of 
neurological disorders and stroke rt-pa stroke study group. N Engl J Med. 
1995;333:1581-1587 
33. Brown DL, Johnston KC, Wagner DP, Haley EC, Jr. Predicting major neurological 
improvement with intravenous recombinant tissue plasminogen activator treatment of 
stroke. Stroke. 2004;35:147-150 
34. TriMatch: BJ. An r package for propensity score matching of non-binary treatments. 
2014 
35. Rosenbaum PRR, D. B. The central role of the propensity score in observational 
studies for causal effects. Biometrika. 1983;70:41–55 
36. Efron B. Bootstrap methods: Another look at the jackknife. Annals of Statistics. 
1979;7:1–26 
37. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley & Sons; 
1987. 
38. Stuart EA. Matching methods for causal inference: A review and a look forward. 
Statistical Science. 2010;25:1-21 
39. Šidák Z. Rectangular confidence regions for the means of multivariate normal 
distributions. Journal of the American Statistical Association. 1967:626–633  
40. Strbian D, Michel P, Seiffge DJ, Saver JL, Numminen H, Meretoja A, Murao K, 
Weder B, Forss N, Parkkila AK, Eskandari A, Cordonnier C, Davis SM, Engelter ST, 
Tatlisumak T. Symptomatic intracranial hemorrhage after stroke thrombolysis: 
Comparison of prediction scores. Stroke. 2014;45:752-758 
41. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees 
KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D. 
Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 
2008;359:1317-1329 
42. Ploen R, Sun L, Zhou W, Heitmeier S, Zorn M, Jenetzky E, Veltkamp R. Rivaroxaban 
does not increase hemorrhage after thrombolysis in experimental ischemic stroke. 
Journal of cerebral blood flow and metabolism : official journal of the International 
Society of Cerebral Blood Flow and Metabolism. 2013 
43. Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, Kurata T, Hishikawa 
N, Abe K. Rivaroxaban and apixaban reduce hemorrhagic transformation after 
thrombolysis by protection of neurovascular unit in rat. Stroke. 2014 
44. Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-
Last E, Steinmetz H, Foerch C. Thrombolysis with recombinant tissue plasminogen 
20 
 
activator under dabigatran anticoagulation in experimental stroke. Annals of 
neurology. 2012;71:624-633 
45. Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R. Anticoagulation with dabigatran does 
not increase secondary intracerebral haemorrhage after thrombolysis in experimental 
cerebral ischaemia. Thromb Haemost. 2013;110:153-161 
46. Rybinnik I, Mullen MT, Messe S, Kasner SE, Cucchiara B. Treatment of acute stroke 
in patients on dabigatran: A survey of us stroke specialists. Journal of stroke and 
cerebrovascular diseases : the official journal of National Stroke Association. 
2013;22:1312-1316 
47. Harenberg J, Kraemer R. Measurement of the new anticoagulants. Thrombosis 
research. 2012;129 Suppl 1:S106-113 
48. De Marchis GM, Jung S, Colucci G, Meier N, Fischer U, Weck A, Mono ML, 
Galimanis A, Mattle HP, Schroth G, Gralla J, Arnold M, Brekenfeld C. Intracranial 
hemorrhage, outcome, and mortality after intra-arterial therapy for acute ischemic 
stroke in patients under oral anticoagulants. Stroke. 2011;42:3061-3066 
49. Nogueira RG, Smith WS. Safety and efficacy of endovascular thrombectomy in 
patients with abnormal hemostasis: Pooled analysis of the merci and multi merci trials. 
Stroke. 2009;40:516-522 
 
 
